409 related articles for article (PubMed ID: 9263748)
1. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia.
Karabina SA; Elisaf M; Bairaktari E; Tzallas C; Siamopoulos KC; Tselepis AD
Eur J Clin Invest; 1997 Jul; 27(7):595-602. PubMed ID: 9263748
[TBL] [Abstract][Full Text] [Related]
2. Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractions.
Karabina SA; Liapikos TA; Grekas G; Goudevenos J; Tselepis AD
Biochim Biophys Acta; 1994 Jun; 1213(1):34-8. PubMed ID: 8011677
[TBL] [Abstract][Full Text] [Related]
3. PAF-acetylhydrolase activity of Lp(a) before and during Cu(2+)-induced oxidative modification in vitro.
Karabina SA; Elisaf MC; Goudevenos J; Siamopoulos KC; Sideris D; Tselepis AD
Atherosclerosis; 1996 Aug; 125(1):121-34. PubMed ID: 8831934
[TBL] [Abstract][Full Text] [Related]
4. Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia.
Tsimihodimos V; Karabina SA; Tambaki AP; Bairaktari E; Miltiadous G; Goudevenos JA; Cariolou MA; Chapman MJ; Tselepis AD; Elisaf M
J Lipid Res; 2002 Feb; 43(2):256-63. PubMed ID: 11861667
[TBL] [Abstract][Full Text] [Related]
5. Dissociable and nondissociable forms of platelet-activating factor acetylhydrolase in human plasma LDL: implications for LDL oxidative susceptibility.
McCall MR; La Belle M; Forte TM; Krauss RM; Takanami Y; Tribble DL
Biochim Biophys Acta; 1999 Jan; 1437(1):23-36. PubMed ID: 9931415
[TBL] [Abstract][Full Text] [Related]
6. Platelet-activating factor acetylhydrolase and transacetylase activities in human plasma low-density lipoprotein.
Tsoukatos DC; Liapikos TA; Tselepis AD; Chapman MJ; Ninio E
Biochem J; 2001 Jul; 357(Pt 2):457-64. PubMed ID: 11439095
[TBL] [Abstract][Full Text] [Related]
7. Oxidative structural modifications of low density lipoprotein in homozygous familial hypercholesterolemia.
Napoli C; Postiglione A; Triggiani M; Corso G; Palumbo G; Carbone V; Ruocco A; Ambrosio G; Montefusco S; Malorni A; Condorelli M; Chiariello M
Atherosclerosis; 1995 Dec; 118(2):259-73. PubMed ID: 8770320
[TBL] [Abstract][Full Text] [Related]
8. Oxidizability of atherogenic low-density lipoprotein subspecies in severe familial hypercholesterolemia: impact of long-term low-density lipoprotein apheresis.
Lepage S; Nigon F; Bonnefont-Rousselot D; Assogba U; Goulinet S; Chancharme L; Delattre J; Bruckert E; Chapman MJ
J Cardiovasc Pharmacol Ther; 2000 Apr; 5(2):87-103. PubMed ID: 11150388
[TBL] [Abstract][Full Text] [Related]
9. Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration.
Zhang B; Fan P; Shimoji E; Itabe H; Miura S; Uehara Y; Matsunaga A; Saku K
Atherosclerosis; 2006 Jun; 186(2):291-301. PubMed ID: 16154574
[TBL] [Abstract][Full Text] [Related]
10. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis.
Liberopoulos EN; Papavasiliou E; Miltiadous GA; Cariolou M; Siamopoulos KC; Tselepis AD; Elisaf MS
Perit Dial Int; 2004; 24(6):580-9. PubMed ID: 15559488
[TBL] [Abstract][Full Text] [Related]
11. The low-density lipoprotein (LDL)-associated PAF-acetylhydrolase activity and the extent of LDL oxidation are important determinants of the autoantibody titers against oxidized LDL in patients with coronary artery disease.
Lourida ES; Papathanasiou AI; Goudevenos JA; Tselepis AD
Prostaglandins Leukot Essent Fatty Acids; 2006 Aug; 75(2):117-26. PubMed ID: 16843649
[TBL] [Abstract][Full Text] [Related]
12. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.
Milionis HJ; Elisaf MS; Karabina SA; Bairaktari E; Tselepis AD; Siamopoulos KC
Kidney Int; 1999 Dec; 56(6):2276-85. PubMed ID: 10594806
[TBL] [Abstract][Full Text] [Related]
13. Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment.
de Graaf J; Hendriks JC; Demacker PN; Stalenhoef AF
Arterioscler Thromb; 1993 May; 13(5):712-9. PubMed ID: 8485123
[TBL] [Abstract][Full Text] [Related]
14. The effect of simvastatin treatment on the low-density lipoprotein subfraction profile and composition in familial hypercholesterolaemia.
de Graaf J; Demacker PN; Stalenhoef AF
Neth J Med; 1993 Dec; 43(5-6):254-61. PubMed ID: 8107933
[TBL] [Abstract][Full Text] [Related]
15. Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins.
Guerra R; Zhao B; Mooser V; Stafforini D; Johnston JM; Cohen JC
J Lipid Res; 1997 Nov; 38(11):2281-8. PubMed ID: 9392426
[TBL] [Abstract][Full Text] [Related]
16. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects.
de Graaf J; Hak-Lemmers HL; Hectors MP; Demacker PN; Hendriks JC; Stalenhoef AF
Arterioscler Thromb; 1991; 11(2):298-306. PubMed ID: 1998647
[TBL] [Abstract][Full Text] [Related]
17. Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia.
van Tits LJ; Smilde TJ; van Wissen S; de Graaf J; Kastelein JJ; Stalenhoef AF
J Investig Med; 2004 Apr; 52(3):177-84. PubMed ID: 15222407
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.
Tsimihodimos V; Karabina SA; Tambaki AP; Bairaktari E; Goudevenos JA; Chapman MJ; Elisaf M; Tselepis AD
Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):306-11. PubMed ID: 11834533
[TBL] [Abstract][Full Text] [Related]
19. Increased platelet reactivity to the aggregatory effect of platelet activating factor, in vitro, in patients with heterozygous familial hypercholesterolaemia.
Elisaf M; Karabina SA; Bairaktari E; Goudevenos JA; Siamopoulos KC; Tselepis AD
Platelets; 1999; 10(2-3):124-31. PubMed ID: 16801081
[TBL] [Abstract][Full Text] [Related]
20. Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction.
Benítez S; Sánchez-Quesada JL; Ribas V; Jorba O; Blanco-Vaca F; González-Sastre F; Ordóñez-Llanos J
Circulation; 2003 Jul; 108(1):92-6. PubMed ID: 12821559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
